Top Metformin Brands: The Ultimate Guide

Metformin is one of the most prescribed medications for managing type 2 diabetes due to its efficacy and safety profile. As patients explore their options, choosing the right brand becomes paramount for both effectiveness and affordability. With numerous options available, it can be a daunting task to sift through the myriad of brands in the market. To guide you in this process, we have compiled a list of some of the best metformin brands known for their quality and reliability. Discover which brands top the list below.

Illustration of metformin

Best brands of metformin in 2025

Glucophage

Glucophage, a brand name for metformin, is a leading product in the treatment of type 2 diabetes, having been on the market since 1957 in France and introduced in China in 1994. It is recognized for its effectiveness in lowering blood glucose levels by reducing liver glucose production, enhancing insulin sensitivity, and diminishing intestinal absorption. Glucophage is often prescribed as a first-line treatment, recommended by the American Diabetes Association and the World Health Organization, due to its favorable risk-benefit profile and high adherence rate. The drug is available in both immediate- and extended-release formulations, such as Glucophage XR, and has a bioavailability of 50% to 60% under fasting conditions. With a significant market share, Glucophage continues to be a crucial medication in managing diabetes globally. For more insights into the metformin market in China from 2021 to 2025, you can explore the detailed report.

Glucophage XR

Glucophage XR, a brand of metformin hydrochloride, is a highly effective oral antihyperglycemic drug used in the management of type 2 diabetes. It is available in 500 mg and 750 mg extended-release tablets, utilizing a dual hydrophilic polymer matrix system for controlled drug release. Approved by the FDA in 2000 and 2003 for the respective strengths, Glucophage XR ensures a steady and prolonged release of metformin, with peak plasma levels achieved within 4 to 8 hours after administration. The drug has been shown to reduce HbA1c levels by up to 0.6% in clinical studies and is known for its favorable safety profile and potential for weight loss. Despite the discontinuation of these specific formulations, Glucophage XR remains a significant brand in the metformin market. For more detailed information, you can view the FDA-approved label.

Fortamet

Fortamet, a brand of metformin hydrochloride, is a leading product in the management of type 2 diabetes, offering extended-release tablets that provide once-a-day oral administration. Developed using patented single-composition osmotic technology (SCOTTM), Fortamet ensures steady and controlled release of the medication, enhancing patient compliance. Available in 500 mg and 1000 mg strengths, Fortamet has been clinically shown to be non-inferior to immediate-release metformin in terms of efficacy, with mean HbA1c changes from baseline to endpoint comparable to traditional formulations. The global metformin market, driven by increasing diabetes prevalence and growing awareness of metformin's benefits, is expected to grow at a CAGR of 6.0% to 7.2% from 2023 to 2030. Fortamet's formulation and performance make it a preferred choice among healthcare professionals and patients. For more detailed information about Fortamet's formulation and usage, you can visit their website.

Riomet

Riomet, a brand of metformin, is recognized for its high quality and efficacy in managing type 2 diabetes. The global metformin market, which includes brands like Riomet, is expected to grow significantly, with a projected market size of USD 6,420.02 billion by 2030, growing at a CAGR of 6.0% from 2023 to 2030. The increasing prevalence of diabetes and heightened awareness about its management are key drivers of this growth. Metformin, including Riomet, is available in various formulations such as standard-release and slow-release tablets, catering to different patient needs. The market expansion is also fueled by the rise in healthcare spending and the aging population requiring diabetes management. For more information, visit the Riomet product page.

Glumetza

Glumetza, a brand of metformin hydrochloride extended-release tablets, is renowned for its effective management of type 2 diabetes. It utilizes an advanced polymer delivery technology, known as AcuForm(r), which allows for once-daily dosing and improves patient adherence by reducing gastrointestinal side effects. In a 24-week study, 60.4% of patients taking Glumetza 2000 mg daily achieved an A1C goal of less than 7%, outperforming immediate-release metformin. This formulation is particularly beneficial as it resides in the stomach for an extended period, releasing the active drug over 8 to 9 hours, enhancing its efficacy. Glumetza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. For more detailed information, you can visit the Glumetza page on RxList.

Metformin Hydrochloride Tablets

Metformin Hydrochloride Tablets, available from various generic brands, are highly regarded for their efficacy and quality. A comparative study revealed that generic and branded metformin tablets, including those from manufacturers like Teva Pharmaceuticals, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries, meet the acceptable range of physical and chemical parameters as per IP specifications. The global market for these tablets, estimated at US$ 3784 million in 2023, is forecasted to reach US$ 2519.3 million by 2030, with a significant presence in regions like North America and Europe. These tablets are available in immediate-release and extended-release forms, catering to diverse patient needs. The increasing demand, driven by the growing number of type-2 diabetes patients, further solidifies their position in the market.

Sandoz Metformin

Sandoz Metformin FC, produced by Sandoz Canada Inc., is a highly regarded formulation of metformin hydrochloride, available in 500 mg and 850 mg film-coated tablets. It is indicated for improving glycemic control in adults with type 2 diabetes, used as an adjunct to diet, exercise, and weight reduction. The product has been a staple in diabetes management for decades, with metformin being the first-line pharmacological treatment for type 2 diabetes, used by approximately 120 million patients worldwide. The market for metformin is expected to grow significantly, with a projected compound annual growth rate (CAGR) of 7.2% from 2023 to 2028. Sandoz's formulation is known for its safety profile and efficacy, making it a preferred choice among healthcare providers. For detailed product information, visit the Sandoz Metformin FC page.

Accord Metformin

Accord Metformin, a product of Intas Pharmaceuticals Ltd., is a prominent player in the global metformin market, known for its high-quality and affordable metformin hydrochloride tablets. The global metformin market, which was valued at USD 4,028 million in 2022, is expected to grow at a CAGR of 6.0% to reach USD 6,420.02 billion by 2030, driven by increasing diabetes prevalence and the aging population. Accord Metformin is available in various dosage forms, including standard-release and slow-release tablets, catering to different patient needs. The product is widely distributed through hospital pharmacies, retail pharmacies, and online pharmacies, ensuring broad accessibility. With its effective and safe profile, Accord Metformin remains a preferred choice among healthcare professionals and patients. For more details, visit their Accord Metformin page.

Aurobindo Metformin

Aurobindo Metformin is a highly regarded brand in the metformin market, known for its high-quality film-coated tablets available in 500mg, 850mg, and 1000mg strengths. These tablets are indicated for the treatment of type 2 diabetes mellitus, particularly in overweight patients, and can be used as monotherapy or in combination with other oral anti-diabetic agents or insulin. The product has been authorized in the Netherlands since 27 April 2006 and has demonstrated bioequivalence to the well-established brand Glucophage. Aurobindo Metformin has shown a reduction in diabetic complications in overweight type 2 diabetic adult patients, highlighting its efficacy. The metformin market, which includes Aurobindo Metformin, is expected to grow significantly, with a projected market size of $5.5 billion by 2028 at a CAGR of 7.2%. For more details, you can visit their official site.

Lupin Metformin

Lupin, a leading pharmaceutical company, stands out as a prominent producer of metformin, particularly with its launch of generic Metformin HCl ER Tablets, which are the AB-rated generic equivalent of Santarus Inc.'s Glumetza® HCl ER Tablets. These tablets are indicated for improving glycemic control in adults with type II diabetes mellitus and come in 500 mg and 1000 mg strengths. Lupin holds a significant market share, being the 6th largest generic pharmaceutical player in the US with a 5.5% market share by prescriptions as of recent years. The company's Metformin HCl ER Tablets are part of its extensive portfolio, contributing to its strong presence in the diabetology segment. Lupin's commitment to delivering high-quality, affordable generic medicines has made it a trusted name in the healthcare industry. For more information, visit Lupin's official announcement on the launch of Generic Glumetza HCl ER Tablets.